WuXi AppTec has acquired HD Biosciences, a biology-focused preclinical drug discovery contract research organization (CRO), which will become a wholly-owned subsidiary of WuXi, and will continue to focus on growing its core competences. The acquisition will further strengthen WuXi’s R&D capability from target validation to lead discovery and optimization, and expands its open-access enabling service platform. Founded in 2002, HD Biosciences is headquartered in Shanghai with operatin...